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Abstract 
The adoption of evidence-based hierarchies and research methods from other 
disciplines may not completely translate to complex palliative care settings. The 
heterogeneity of the palliative care population, complexity of clinical presentations and 
fluctuating health states present significant research challenges.  
The aim of this narrative review is to explore the debate about the use of current 
evidence-based approaches for conducting research, such as RCTs and other study 
designs, in palliative care, and more specifically to (a) describe key myths about 
palliative care research; (b) highlight substantive challenges of conducting palliative 
care research, using case illustrations; and (c) propose specific strategies to address 
some of these challenges. 
Myths about research in palliative care revolve around evidence hierarchies, sample 
heterogeneity, random assignment, participant burden and measurement issues. 
Challenges arise because of the complex physical, psychological, existential and 
spiritual problems faced by patients, families and service providers. These challenges 
2 
 
can be organized according to six general domains: patient, system/organization, 
context/setting, study design, research team and ethics. A number of approaches for 
dealing with challenges in conducting research fall into five separate domains: study 
design, sampling, conceptual, statistical, and measures and outcomes.  
Although RCTs have their place whenever possible, alternative designs may offer more 
feasible research protocols that can be successfully implemented in palliative care. 
Therefore, this article highlights ‘outside the box’ approaches that would benefit both 
clinicians and researchers in the palliative care field. Ultimately, the selection of 
research designs is dependent on a clearly articulated research question, which drives 




Each science must develop a set of techniques, methods, procedures and theories, 
which are appropriate for understanding the characteristics of the subject matter of the 
discipline 1. 
To influence clinical practice in palliative care, clinicians need to have access to the 
“best” evidence. However, acquiring this evidence presents particular problems and the 
discipline of palliative care urgently requires a wider evidence base. Aoun and 
Kristjanson 2, 3 examined the debate about best evidence within the public health 
literature. They proposed that similar arguments and concerns exist with respect to the 
use of current evidence-based approaches for implementing research and evaluating 
the literature in palliative care. 
More recently, Hui and colleagues 4, 5 examined the quality, design and scope of the 
palliative literature in a systematic review of 1,213 articles, spanning two time periods: 6 
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months in 2004 and 6 months in 2009. The four most common study designs from the 
evidence hierarchy (Figure 1) were: Case report/series (51%), cross-sectional surveys 
(18%), qualitative studies (11%), and cohort studies (9%). Randomized controlled trials 
(RCTs) comprised only 6% of all studies, the majority of which focused on interventions 
for physical symptoms with a median sample size of only 70 participants. Other aspects 
of palliative care, including communication, decision making/ethics, education, research 
methodology, and spirituality represented 5% or less of all RCTs. The authors 
concluded that there are critical concerns about the current state of knowledge 
conception with the overall methodological quality of RCTs being poor. The Cochrane 
systematic reviews in palliative care failed “to provide good evidence for clinical practice 
because the primary studies are few in number, small, clinically heterogeneous, and of 
poor quality and external validity” (p. 8).  
 
(Insert figure 1 about here) 
 
The most recent Cochrane review on the effectiveness of home palliative care 
services has raised similar methodological concerns 6. Based on a review of 23 studies 
(37,561 patients and 4,042 caregivers), there was strong evidence to demonstrate that 
these services supported an increased number of patients dying at home and reduced 
symptom burden, without increasing caregiver grief. However, the evidence was not 
conclusive on nine other patient and caregiver outcomes due to a number of 
methodological issues. Therefore, there is a great need for high-quality evidence to 
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support everyday clinical practice and a need to conduct more studies on caregivers, 
health care professionals, and psychosocial-spiritual topics in palliative care. 
Over the past two decades, numerous concerns regarding methodological issues 
and debates about the role of evidence-based approaches in palliative care research 
have been raised 7-21. The purpose of this narrative review is to further explore the 
debate about the use of current evidence-based approaches, such as RCTs, for 
conducting research and evaluating the literature in palliative care, by addressing the 
following three questions: 
 What are some myths about palliative care research? 
 What are the challenges of conducting palliative care research? 
 What strategies can be used to address these challenges? 
We will begin with a description of five myths associated with palliative care 
research, followed by a summary of specific research challenges and strategies. To 
illustrate some of the challenges and corresponding strategies, we will present 
examples of research projects undertaken in different settings at the regional and 
international levels over the past 10 years. 
 
What are some of the myths about palliative care research? 
Five myths that have potentially held back advances in the number, quality and 
diversity of palliative care research revolve around evidence hierarchies, sample 





Myth1: RCTs and systematic reviews are the highest (best) level of evidence. 
Palliative care researchers have drawn from many methods outside of the 
discipline, such as the basic and social sciences, to conduct palliative care research. 
The adoption of hierarchical frameworks, such as evidence-based medicine, in which 
RCTs and systematic reviews of RCTs are considered the “gold standard” representing 
the highest or best levels of evidence 22, have created significant challenges in palliative 
care.  
In a 25 year retrospective review of their research program, Bruera and Hui 23 
suggested that some of their most useful research for patients and families was 
retrospective. Some of the most important questions either did not receive funding from 
industry or granting agencies, or were not appropriate for RCTs. Ahmedzai 24 has also 
suggested that RCTs may not always be appropriate, particularly for unique clinical 
cases in which urgent decisions need to be made despite a lack of evidence. 
 
Myth 2: Homogeneous samples are preferred over heterogeneous samples. 
Palliative care patients represent a unique cohort, consisting of multiple disease 
states and co-morbidities; diverse symptom profiles; fluctuating cognitive and functional 
status; and broad age ranges. The heterogeneity of this population presents significant 
research challenges 12, 15. From a methodological perspective, homogeneous samples 
are preferred, in an effort to control extraneous variables. From a clinical perspective, 
however, the use of heterogeneous samples more closely approximates the clinical 
setting, with the findings being more representative and generalizable to diverse 




Myth 3: Random assignment ensures group equivalency. 
Random assignment involves the use of a standard method, such as random 
number generators, for ensuring that each person has an equal chance of being 
assigned to each intervention. In RCTs, the use of appropriate random assignment 
procedures can control for the heterogeneity of palliative care populations by evenly 
distributing this heterogeneity across all groups 12.  
Despite being one of the best approaches for obtaining initial equivalency between 
different intervention groups, random assignment does not ensure group equivalency. 
Ineffective randomization procedures, small sample sizes, large within-group 
heterogeneity, different attrition rates between groups and potential threats to internal 
validity associated with control groups may create substantial barriers for obtaining and 
maintaining equivalent groups 25. Additional approaches to ensure initial group 
equivalency, such as stratification, matching and increased sample sizes, may be 
warranted. Cluster sampling or randomization might also be effective when it is more 
feasible to select intact groups rather than individuals; however, special statistical 
analyses are needed to adjust for intra-cluster variability and may be less sensitive in 
detecting individual differences.25 The use of desirable alternative or delayed 
interventions for control groups, such as randomized fast-track52 or wait-list12 designs, 
as well as intention-to-treat analysis, may be useful for maintaining group equivalency 
over time. Fast track or wait list designs ensure that all participants receive the 
treatment. However, these designs are most appropriate for patients with relatively 




Myth 4: Research can be an additional and unwanted burden on patients and family 
members. 
Ethical concerns regarding the involvement of vulnerable, medically frail patients 
and their families in palliative care research are often raised. These concerns revolve 
around increased patient burden, potential distress and even harm that may be 
associated with taking part in research 26; and are often raised by healthcare providers 
and family members 27. Less is known about the patients’ perspectives. 
Hudson et al. 28 point to three levels of gatekeeping - institutional, professional, and 
patient and family gatekeeping - that have undermined the representativeness of 
research samples and the ability to generalize from research. According to Sharkey et 
al. 29, clinician gate-keeping violates three principles that underpin international ethical 
guidelines: respect for persons’ autonomy; beneficence (a favourable balance of risks 
and potential benefits); and justice (a fair distribution of the benefits and burdens of 
research). 
In a systematic review, White and Hardy 27 identified eight studies focusing on the 
views of palliative care patients and their families towards research. Two themes 
relating to the benefits of participating in research that emerged from this review were 
the potential for personal gain and altruism. Additional themes included the desire to 
maintain autonomy and to avoid complex studies. Pessin et al. 30 interviewed 68 
advanced cancer patients regarding participation in psychosocial research. Most 
participants reported no burden associated with participation (75%) and found it to be 
moderately to highly beneficial (68%). Almost three quarters of participating caregivers 
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in Hudson’s study 31 identified benefits to their dying relative, themselves and for future 
families in need of palliative care. These findings further contribute to other reports 
highlighting patients’ interest in and enhanced benefits of taking part in research 15, 32. 
 
Myth 5: Only factors that can be measured are important.  
The principles of measurement initially evolved from the use of quantitative 
research designs, in which concepts were operationally defined and evaluated using 
appropriate outcome measures. With the advent of evidence-based medicine (EBM), 
the reliance on RCTs and systematic reviews as the highest level of evidence implicitly 
suggests that only those variables that can be measured are important 33.  
The development of assessment tools and outcome measures in palliative care has 
grown substantially, which has provided researchers with many options for instrument 
selection. In most clinical oncology drug trials, quality of life is now included as an 
outcome measure in trial designs, endorsing the importance of evaluating clinically 
relevant psychosocial-spiritual outcomes in intervention studies 34. Accompanying this 
rapid development, however, researchers are often challenged with selecting an 
appropriate measure from a plethora of instruments, many of which do not have 
adequate validity evidence in palliative care settings 35. The selection of outcome 
measures that adequately capture complex psychosocial-spiritual concepts is equally 
challenging 36. Other approaches for understanding the complexity of patients’ and 
family members’ experiences that do not primarily rely on quantitative assessments and 
measures, including qualitative research methods, can also contribute to the 
advancement of palliative care 19, 37. It is also worth pointing out that qualitative studies 
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provide important preliminary data to inform the development and subsequent validation 
of quantitative surveys. 
 
What are some of the challenges of conducting palliative care research? 
Substantial challenges associated with conducting palliative care research have 
been previously described in the literature 7-21. These challenges can be organized 
according to six general domains, as outlined in Table 1: (a) patient, (b) 
system/organization, (c) context/setting, (d) study design, (e) research team and (f) 
ethics. 
[Insert Table 1 about here] 
Patient factors include varying and unclear definitions for palliative care patients, 
population heterogeneity, frailty, and fluctuating clinical and cognitive status. In some 
cases, patient preferences to participate in disease-modifying, rather than symptom 
management, research, might also hinder recruitment 38. Organizational factors often 
relate to complex ethical approval processes, undeveloped research cultures and 
segregated palliative care services. The limited availability and inherent competitiveness 
of research funding opportunities may create additional organizational barriers 39, 40. 
Each setting has its own unique challenges in which competing clinical demands, 
opposing styles of practice, limited resources and lack of interest may impede the 
integration of research agendas within clinical settings. Study design issues revolve 
around restricted patient eligibility and recruitment, patient attrition, inappropriate 
randomization, blinding and use of placebos, difficulty controlling for interventions and 
lack of appropriate outcomes. Recruitment, training, availability and turnover of research 
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staff can influence research team dynamics. Finally, ethical issues, such as obtaining 
patient consent, patient safety and inability to withhold treatment, further contribute to 
these extensive research challenges. Given the fluctuating cognitive status of many 
palliative patients, the assessment of patients’ cognitive status and understanding of 
their study involvement is paramount in studies where informed consent is required. 
Researchers need to carefully consider safety issues, targeting an acceptable balance 
between patient risks and benefits. Further treatments that have low toxicity profiles in 
non-palliative patients may not be well-tolerated in palliative care populations 41.  
 
Walshe 21 highlighted several challenges in using standard experimental methods 
for the evaluation of complex interventions in palliative care: 
 Services change with time and are not used or provided consistently. Patients 
can receive a number of services from various providers at the same time or at 
different times leading to difficulties in determining the extent and nature of the 
treatment. 
 Randomization or identification of a suitable comparison group is problematic, as 
there may not be enough providers to recruit from, in addition to the ethical 
issues regarding withholding services that are already being provided (e.g. when 
evaluating an existing program). If all patients in the program are already 
receiving the service, then it may be difficult to find a suitable comparison group 
outside the program. It would also not be feasible (or ethical) to withhold services 
from patients within the program.  
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 The sole use of quantitative experimental approaches gives little information 
about causation and about why certain effects were or were not observed. They 
also tend to investigate isolated components of a complex system and not the 
complicated relationships between components. 
 The declining health status of participants leads to difficulties with attrition, 
retention or interrupted follow up. A high level of attrition prohibits the generation 
of sufficient data for a powered analysis. 
 
In addition to these challenges, there is the issue of equipoise. One of the key 
principles of RCTs is a state of clinical equipoise, which means that no preference 
for any particular treatment arm can occur 42. However, a state of clinical equipoise 
is difficult to achieve in studies designed to test complex interventions that are not 
amenable to blinding, as is possible for RCTs designed to test different medical 
interventions, such as clinical drug trials. Complex interventions require informed 
and motivated participants and professionals to engage in the process. In palliative 
care research, controlling confounding effects, as is the case in clinical drug trials 
using RCT design are seldom feasible, justifiable or acceptable to the patient. 
Patients with cancer and their families may not wish to risk reducing the quality of life 
of their remaining days by participating in a trial with an uncertain outcome. 
Practitioners may not wish to randomise their patients to treatments in which they 
lack confidence. Few of them have neutral views about the differences between two 
or more treatments; hence, clinical equipoise, a requirement of RCTs, may be 
impossible to achieve. No systematic review has yet integrated the evidence on 
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participants’ and professionals’ preferences for particular treatments as modifiers of 
outcome in randomised trials42. 
To address these challenges, Walshe21 proposed the use of case study research. 
Case study designs are context-driven, rather than method-driven, most commonly 
being defined by the selected case. This type of research design has the potential to 
integrate a diversity of quantitative and qualitative methods and data, providing rich 
understandings from diverse perspectives.   
 
The following three case examples of complex psychological, pharmacological and 
health services intervention studies, respectively, illustrate several of these 
methodological challenges, with more details reported on the development and 
evaluation of Case 3. 
 
Case 1: Dignity Therapy- psychological intervention 
Dignity Therapy is an intervention consisting of interviewing palliative care patients 
using a series of guided questions about their life and past events that are important to 
them, resulting in the production of an edited generativity document that could be 
shared with family members and service providers 43. A randomized controlled trial to 
test the effectiveness of dignity therapy for the terminally ill was conducted in Canada, 
the United States and Australia (n=326), with three comparison groups: the dignity 
therapy intervention, client centred care and standard care 44. There were no significant 
differences between the three groups in terms of the primary outcome of distress. The 
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authors reported that due to the low base rate of distress within the sample, there was 
no room for improvement. 
However, Nekolaichuk 36 highlighted some substantial impediments for research 
into psychosocial interventions such as dignity therapy. First, the selection of outcome 
measures that adequately capture complex psychosocial spiritual concepts is 
challenging. Some terminally ill patients might be distressed while simultaneously 
feeling hopeful, and finding meaning in life: Patients have described this apparent 
paradoxical experience in different ways, including being on an emotional living-dying 
pendulum45 or as “latching onto life” in the midst of the possibility of dying 46. Second, 
recruitment is often restricted to articulate, cognitively intact patients; therefore, 
physically frail or highly distressed patients are less likely to participate. A third 
impediment relates to the lack of standardisation of psychosocial interventions across 
several sites. Differences exist in care availability and discipline mix between a 
specialized inpatient tertiary palliative care unit and a home care team. Additionally, 
some psychosocial spiritual interventions in standard care might help relieve patient 
distress in the comparison or control groups. 
 
Case 2: Ketamine Clinical Drug Trial- pharmacological intervention 
Pharmacological clinical trials were undertaken in 10 Australian palliative care 
services to test the clinical benefits of a number of drugs, ketamine for pain relief being 
one of them. The project faced a myriad of protocol and operational issues in all sites. 
These included complex inclusion/exclusion criteria, as patients needed to be on stable 
medications for 48 hours; and variations in clinical assessments and pain adjuvant 
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treatments 47, 48. Many patients did not complete the study due to disease progression; 
in some cases, declining conditions made it difficult for patients to swallow tablets. 
Several reasons for gate keeping by clinicians included the following:  
 The clinical practice not aligning with study protocols. 
 The use of placebo not justifiable. 
 Patients too unwell to be approached for consent. 
 The clinicians’ personal beliefs about the medications and time involved. 
The following operational issues created additional challenges: 
 Patients not under the control of the project chief investigators 
 Difficulty maintaining enthusiasm of staff 
 Difficulty conducting research in services with no research culture 
 Lack of engagement by site investigators 
 Staffing issues in recruitment, training and turnover 
 Pharmaceutical restrictions in which randomization was restricted to certain days 
of the week, time restrictions on when scripts needed in pharmacy and lack of 
availability of drug over weekends 
 
For the 12 months of the ketamine study in Western Australia, 61 people were 
screened, 7 were randomized, and only 4 completed treatment. Reasons for this low 
completion rate included patients not meeting inclusion criteria (e.g. patients were 
already on Ketamine or unstable opioids, undertaking radiotherapy/treatment, having 
dementia or confusion), deteriorating health or declining to participate. Hardy et al. 49 
reported on the national findings of the ketamine study. There were significantly higher 
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rates of toxicity and other side-effects among the 93 patients given ketamine, compared 
with the 92 who were given a placebo. Based on the study findings, it was concluded 
that ketamine did not have a net clinical benefit when used as an adjunct to opioids and 
standard co-analgesics in cancer pain. 
 
In order to enhance the effectiveness of resources applied to palliative and end of 
life research, Hagen et al.41 highlighted several approaches for establishing accrual 
targets and implementing appropriate interventions if study targets are not reached. 
 
Case 3: The Home Alone Study- health service intervention 
This project implemented and evaluated two models of care for terminally-ill people 
living alone at home, compared to routine care: installing personal alarms and providing 
extra care aide support 50. The primary aim was to assess the feasibility of using an 
RCT approach with this group. A secondary aim was to assess the potential impact of 
the models of care on the participants’ quality of life, symptom distress, anxiety and 
depression, and perceived benefits and barriers to their use. The challenges of this 
quantitative approach were numerous: 
• The rapidly changing clinical situations meant shifting the timing of 
measurements and the follow-up session to catch some patients before they 
died, while other patients survived longer than expected. 
• Attrition rates differed between groups as more deaths occurred in the two 
intervention groups than in the control group. 
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• Some patients who were randomised to the care aide group did not really need 
or want this support and care aides were considered more of an intrusion. 
• There was wide variation in the degrees of “home aloneness,” as a significant 
proportion of patients were receiving visits from family and friends either 
occasionally or regularly, be it for a social visit or to get help with household 
tasks. This variation confounded the findings in terms of how much informal 
support each patient was getting over and above the implemented models of 
care that were randomly allocated. Therefore, this created an impediment to 
evaluating the effectiveness of interventions using an RCT approach. 
• Patient recruitment and attrition were hampered due to limited survival times and 
clinician gate-keeping during the recruitment period, with only 43 of 330 potential 
participants completing the study in an 18 month period. 
 
What strategies can be used to address some of the challenges in conducting 
research? 
A number of approaches for dealing with these challenges in conducting research 
are summarized in Table 2, based on reports in the literature. As shown in this table, 
these approaches can be divided into five separate domains: (a) study design, (b) 
sampling, (c) conceptual, (d) statistical analysis and (e) measures and outcomes. 
 
[Insert Table 2 about here] 
(a) Study Design 
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In terms of study design, specific strategies targeting RCTs have been proposed. 
These include general suggestions for designing a clinical trial 51, as well as the use of 
randomized fast-track trials, in which the comparison (control) group is offered the 
intervention at the end of the normal randomized trial 52. The use of enrichment design 
strategies, in which targeted strategies are used to select participants based on the 
presence or absence of specific markers, are being used more frequently in clinical drug 
trials 53, 54. These designs are most appropriate when the new targeted agent’s 
mechanism of action is well known. Crossover designs, which require fewer patients, 
and “N of 1” studies, which individualize treatments, can provide meaningful 
comparisons in which patients serve as their own controls. Both of these designs are 
most appropriate for patients with relatively stable disease and can supplement other 
RCT designs. Davis and Mitchell55 provide a more detailed discussion of these 
alternatives to the classic RCT, highlighting their strengths and weaknesses. 
Others have advocated for the use of research designs other than RCTs 9, 19, 
including case study 21, action research 56, discourse analysis 57, narrative research 58 
and mixed method designs 59. The most recent update of the Medical Research Council 
Framework in the United Kingdom 60 recommended using mixed methods to develop 
and evaluate complex interventions by combining qualitative and quantitative 
approaches: “Wherever possible, evidence should be combined from a variety of 
sources that do not share the same weaknesses” (p. 980). The following is an example 
of how mixed methods have added value when used in developing and evaluating the 
models of care for terminally ill people who live alone (The Home Alone study 
mentioned in the previous section). 
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The first phase of this study consisted of scoping the problem in three large 
community-based palliative care services in Australia. This was achieved by analysis of 
services records of 721 home alone clients, where the demographic and clinical profiles, 
the services provided, hospitalisations and place of death were ascertained 61. This was 
followed by in-depth interviews with a small number of patients and service providers to 
assess unmet needs and gaps in service provision 62, 63. Based on these findings, a 
questionnaire was then developed and posted to 90 service providers to identify their 
priorities and recommendations for models of care/ interventions. In the second phase, 
two of the recommended models of care were implemented using a three-armed RCT 
approach: installing personal alarm systems (arm 1), providing extra care aide support 
(arm 2) and providing standard care (arm 3) 50. This was followed by in-depth interviews 
with patients and service providers to assess barriers to and benefits of the two models 
of care 63. 
The findings from the qualitative interviews revealed that both models of care could 
meet the physical and psychosocial support needs for home alone patients towards the 
end of their lives. By providing a safer, more secure environment through the use of 
either the personal alarm or the care aide support, patients were able to continue their 
activities of daily living with a degree of independence, while remaining at home 63. This 
example is a useful illustration of the value of mixed methods design where insights 
gained from qualitative (described here) and quantitative (described in previous section) 





Specific strategies to address sampling concerns have focused on the development 
of conceptual frameworks for defining the palliative care population 64, 65, 83, as well as 
the collection and reporting of minimum data sets for reporting patient characteristics in 
the study findings 66-69. The development of a taxonomy to guide clinical trial recruitment 
51 and the use of administrative databases to assess study feasibility 67, 70 have also 
been proposed to improve patient recruitment. 
(c) Conceptual 
Conceptual strategies have focused on approaches for building research capacity 8, 
through the development of innovative partnerships; multidisciplinary research teams 
involving researchers, clinicians, basic scientists and social scientists 8, 71; and 
international collaborations 8, 72, 73. Some have emphasized the importance of 
progressing in incremental steps 8 and the use of different frameworks for assessing 
evidence, such as equity-based frameworks 3 or Jonas’ 74 concept of an “evidence 
house.” Jonas offers a compelling argument for considering an “evidence house,” rather 
than an evidence hierarchy, consisting of many “rooms” or types of research methods 
that may equally be used as evidence for research, depending upon the purpose.  
(d) Statistical Analysis 
Statistical analysis of palliative care findings may present substantive challenges. 
Preston and colleagues identified three key areas as being potentially problematic for 
statistical analyses in palliative and end-of-life care research: missing data, attrition and 
response shifts 75. In a review of 18 clinical trials (n=1214), Hui et al. 76 described a 
median attrition rate of 28% and 44% for primary and end-of-study outcomes, 
respectively. The two main reasons for attrition were patient withdrawal, most commonly 
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due to high symptom burden, and clinical deterioration. Other statistical analysis issues 
that need to be considered include the importance of clinical relevancy (minimal 
clinically important differences) 77, 78 as opposed to purely statistical significance of 
findings; regression towards the mean for extreme scores 25; and the shape and 
variance of the sample distribution in relation to the expected normal population 
distribution.25 
Statistical approaches have largely focused on strategies for dealing with missing 
data and attrition, as illustrated through palliative care case presentations 79, 80. Based 
on a consultation workshop with experts in statistical methods in palliative and end-of-
life care, specific recommendations for managing missing data and attrition have also 
been proposed 75.  
(e) Measures and Outcomes 
The selection of appropriate measures and outcomes continues to be problematic 
due to the diversity of available tools, and, in many cases, limited reliability and validity 
evidence in palliative care settings. Varying scale formats and instrument time frames 
can complicate score interpretation, particularly with cross study comparisons. One 
approach for addressing these issues is the use of standard measures for recording 
clinical outcomes 8, which could then be used as a framework for research designs and 
program evaluation. The development and validation of the Edmonton Classification 
System for Cancer Pain (ECS-CP) illustrates this approach 70, 81. The requirement for 
patient consent was waived by the ethics review boards, as all of the study variables 
were part of routine assessments in clinical practice. Thus, all patients admitted to the 
palliative care services were included in the study designs. 
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The development of minimum datasets for describing research studies could further 
facilitate multi-site collaborations and cross-study comparisons. As an example, Currow 
and colleagues 82 have proposed a generalizability framework for classifying palliative 
care research, consisting of five domains: (a) patient and caregiver, (b) professional, (c) 
service, (d) health and social policy, and (e) research. Within each domain, core and 




This narrative review highlighted some of the potential myths and challenges 
associated with conducting palliative care research, accompanied by some effective 
“out of the box” strategies for designing studies in this complex field. Although RCTs 
and systematic reviews represent an important source of evidence, they may not always 
be appropriate for certain research questions and palliative care settings. Research 
designs need to take into account the unique qualities and culture of each setting. 
Whenever possible, pilot feasibility studies need to be conducted to determine whether 
or not a particular setting is appropriate for the proposed research. The integration of 
routine assessments into clinical practice and the maintenance of clinical administrative 
databases can complement the development of clinically-based research programs.  
The realities of conducting research in complex, palliative care settings will continue 
to challenge researchers. The ideal principles of research methodologies and study 
designs, many of which originated from other disciplines, are not readily transferable to 
palliative care. Researchers will continue to be confronted with difficult decisions, often 
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weighing research ideals with clinical realities. There are a number of ongoing issues, 
which will continue to challenge researchers in this area, in line with the following 
dichotomies: 
 individual versus population-based focus 
 homogeneous (e.g. single tumour group, specific palliative care setting or stage 
of cancer) versus heterogeneous samples (e.g. multiple disease states, different 
illness courses, diverse symptom profiles) 
 single versus multiple interventions 
 outcome versus process 
A summary of these dichotomies and corresponding questions appears in Table 3. 
 
[Insert Table 3 about here] 
 
Ultimately, it is the research question, which is clearly articulated and clinically 
relevant, that provides a guiding framework for developing the research design and 
conducting the study. Future work needs to address how we grade studies in palliative 
care to guide practice, when most studies are at a lower level of evidence than RCTs 
and systematic reviews. If studies are to be fairly and accurately graded for the 
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Table 1. Challenges of conducting palliative care research  




 defining the palliative care patient (timing, 
terminology) 
 
8, 64, 65, 83 
  heterogeneity of the population 12, 15, 20 
  frailty 7 
  unpredictable clinical course and declining health 15 
  increased prevalence of cognitive impairment, 
particularly with advancing disease 
15 
  individual patient preferences to participate in 







 complicated or complex processes for obtaining 




  undeveloped research culture or lack of 
awareness of relevancy of research 
9 
  service delivery of palliative care services, which 
is not integrated or which has undergone 
substantial change 
47, 48 





 gatekeeping by clinicians or family members  
 
28, 29 
  clinical practice does not align with protocols  47, 48 
  increased workload for clinicians (e.g. medical 
assessments by clinicians required) 
47, 48 
  limited or unavailable staff on weekends 
(research and clinical staff) 
47, 48 




 Patient eligibility and recruitment 
 
10, 14, 20 
 o complex inclusion and exclusion criteria, 
which may prevent many patients from being 
eligible for the study 
20 
 o recruitment of “super patients” 20 
  Patient attrition  
 o high attrition rates due to progressive disease 14, 20, 75, 76 
 o dealing with missing data 75, 79, 80 
  Randomization 





  Blinding and use of placebos 
o use of placebo cannot be justified 
12 
  Interventions  
 o patients in control arm or comparison arm 
may perform better due to participation in 
study or benefit of intervention 
20 
 o difficulty standardizing complex interventions, 
particularly psychosocial spiritual 
interventions 
12, 20 
 o difficulty controlling for non-specific 
therapeutic factors, such as the therapeutic 
relationship 
36 
 o difficulty designing appropriate interventions 
due to lack of understanding of complex 
pathophysiology 
12 
  Selection of appropriate outcomes 
o lack of appropriate outcome measures that 
adequately capture complex concepts such 
as psychosocial spiritual issues 










  lack of specific training of research staff in clinical 
trials 
47, 48 






 obtaining patient consent & patient safety 










Table 2. Strategies for dealing with challenges in conducting palliative care 
research 




 Specific strategies for RCTs 
 
 
 o randomized fast-track or wait list trial 12, 52 
 o additional strategies for designing a clinical 
trial 
51 
 o enrichment design strategies 53, 54 
 o crossover design 55 
 o “N of 1” design 55 
 o Cluster randomization/sampling 25, 55 
 
  use of study designs other than RCTs 9, 19 
 o case study 21 
 o action research 56 
 o discourse analysis 57 
 o narrative research 58 




  use of multicentre data collection sites 8, 15 








  collection and reporting of minimum data sets 66-69 
  taxonomy to guide clinical trial recruitment 51 






 innovative partnerships 
 
8, 71 
  multidisciplinary research teams, involving 
researchers (including basic scientists, social 
scientists) and clinicians 
8, 71 
  building research capacity, including 
international collaborations  
8, 72, 73 
  progressing in incremental steps 8 
  different frameworks for assessing evidence  
 o equity-based framework 3 




 handling missing data, attrition and response 
 




  reporting minimal clinically important 
differences 
77, 78 
  regression towards the mean 25 






 recording clinical outcomes using standard 
measures 
 
8, 70, 81 





Table 3. Research Dichotomies 






 What is the purpose of the research? 
 How important is it that the findings be generalizable to 
other settings? 
 How can these findings be applied in a clinical setting? 







 How important is it to obtain a homogeneous sample (e.g. 
single disease and/or tumour group)? How might this 
restriction limit the generalizability of the findings to other 
palliative care patients? 
 How will other extraneous variables, inherent with 
heterogeneous samples, potentially impact the findings? 
 How many of these extraneous variables can be 
controlled? 
 
Single vs. multiple 
interventions 
 
 How can a single intervention be studied, while 
controlling for other confounding variables and clinical 
interventions which are part of standard practice? 
 Is it ethically appropriate to withhold treatment from some 
patients, during the study intervention? 
 
Outcome vs. process 
 
 What outcomes are most appropriate and relevant? 
 Are there quality indicators available for measuring these 
outcomes? What are the psychometric properties of 
these indicators? How appropriate are these indicators 
for palliative care settings? 
 What approaches could be used to capture patients’ and 
family members’ experiences, which may not be 





















Non-randomised trials and 
case control studies=III 
Case series, case studies, qualitative 
research=IV 
